Depósito Académico >
CIMA (Centro de Investigación Médica Aplicada) >
Área de Oncología >
Oncología molecular >
DA - CIMA - Oncología - Oncología molecular - Artículos de Revista >
|Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array|
|Authors: ||Kawamata, N. (N.)|
Ogawa, S. (Seishi)
Gueller, S. (S.)
Ross, S.H. (Samuel H.)
Huynh, T. (T.)
Chen, J. (J.)
Chang, A. (A.)
Nabavi-Nouis, S. (Shayan)
Megrabian, N. (Nairi)
Siebert, R. (Reiner)
Martinez-Climent, J.A. (José Ángel)
Koeffler, H.P. (H. Philip)
|Keywords: ||DNA mutational analysis|
|Issue Date: ||2009|
|Publisher version: ||http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VP8-4WCSRDB-1&_user=766132&_coverDate=08%2F31%2F2009&_rdoc=1&_fmt=high&_orig=gateway&_origin=gateway&_sort=d&_docanchor=&view=c&_acct=C000042418&_version=1&_urlVersion=0&_userid=766132&md5=ecb8ddde361a28fe6be09adc5f3bbd86&searchtype=a|
|Citation: ||Kawamata N, Ogawa S, Gueller S, Ross SH, Huynh T, Chen J, et al. Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Exp Hematol 2009 Aug;37(8):937-946.|
Mantle cell lymphoma (MCL) is a lymphoma characterized by aberrant activation of CCND1/cyclin D1 followed by sequential genetic abnormalities. Genomic abnormalities in MCL have been extensively examined by classical cytogenetics and microarray-based comparative genomic hybridization techniques, pointing out a number of alterations in genomic regions that correlate with the neoplastic phenotype and survival. Recently, single nucleotide polymorphism genomic microarrays (SNP-chip) have been developed and used for analysis of cancer genomics. This technique allows detection of genomic changes with higher resolution, including loss of heterozygosity without changes of gene dosage, so-called acquired uniparental disomy (aUPD).
MATERIALS AND METHODS:
We have examined 33 samples of MCL (28 primary MCL and 5 cell lines) using the 250,000 SNP-chip from Affymetrix.
Known alterations were confirmed by SNP arrays, including deletion of INK4A/ARF, duplication/amplification of MYC, deletion of ATM, and deletion of TP53. We also identified a duplication/amplification that occurred at 13q involving oncogenic microRNA, miR17-92. We found other genomic abnormalities, including duplication/amplification of cyclin D1, del(1p), del(6q), dup(3q) and dup(18q). Our SNP-chip analysis detected these abnormalities at high resolution, allowing us to narrow the size of the commonly deleted regions, including 1p and 6q. Our SNP-chip analysis detected a number of aUPD sites, including whole chromosome 9 aUPD and 9p aUPD. We also found an MCL case with 19p, leading to homozygous deletion of TNFSF genes.
SNP-chip analysis detected in MCL very small genomic gains/losses, as well as aUPDs, which could not be detected by more conventional methods.
|Permanent link: ||http://hdl.handle.net/10171/17893|
|Appears in Collections:||DA - CIMA - Oncología - Oncología molecular - Artículos de Revista|
|Files in This Item:|
There are no files associated with this item.
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.